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Ovarian Hyper-Response to Administration of an GnRH-Agonist 
Without Gonadotropins
Several case reports have indicated that a small subgroup of patients may develop ovarian 
hyperstimulation following the administration of gonadotropin-releasing hormone agonists 
(GnRHa) without gonadotropins. However, since only few such cases have been published, 
it is unclear what course to follow in subsequent cycles after ovarian hyperstimulation in 
the first cycle using only GnRHa. A 33-yr-old woman was referred to in vitro fertilization 
for oocyte donation. A depot preparation (3.75 mg) of tryptorelin without gonadotropins 
induced ovarian multifollicular enlargement with high estradiol level, and was followed by 
human chorionic gonadotropin administration and oocyte retrieval. In a subsequent cycle 
of the same patient, a low dose of tryptorelin (0.05 mg) did not induce ovarian 
hyperstimulation, and resulted in clinical pregnancy. This report shows potential 
management of ovarian hyperstimulation following the administration of GnRHa without 
gonadotropins.
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Since the first report on the use of the combination of gonado-
tropin-releasing hormone agonists (GnRHa) and gonadotropins 
for in vitro fertilization (IVF) in 1984 (1), GnRHa has widely been 
used in controlled ovarian stimulation cycles for assisted repro-
duction. One known complication of pituitary down-regulation 
using GnRHa in IVF treatment cycles is the formation of func-
tional ovarian cysts (2). Several case reports have indicated that 
a very small subgroup of patients may experience ovarian hy-
perstimulation following the administration of GnRHa without 
gonadotropins (3-6). 
  However, since very few case reports have been published on 
this topic, it is unclear what course to follow in subsequent cy-
cles after ovarian hyperstimulation using only GnRHa in the first 
cycle. In the present report, a depot preparation (3.75 mg) of 
tryptorelin without gonadotropins induced ovarian multifollic-
ular enlargement with high estradiol level, and was followed by 
human chorionic gonadotropin (hCG) administration and oo-
cyte retrieval. In a subsequent cycle of the same patient, a low 
dose of triptorelin (0.05 mg) did not induce ovarian hyperstim-
ulation, and resulted in clinical pregnancy.
CASE DESCRIPTION
Our patient was a 33-yr-old nulliparous Korean woman under-
going oocyte donation for her sister on March 2010. The patient 
reported irregular menstrual cycles, with only four to six periods 
each year. Her body mass index was 21.5 kg/m
2, with a gynecoid 
fat distribution. She had mild acne on her face, but no hirsutism, 
virilization, or acanthosis nigricans. Her exam results for the 53rd 
day of her cycle were as follows: negative u-hCG, follicle-stimu-
lating hormone (FSH) 5.39 IU/L, luteinizing hormone (LH) 11.29 
IU/L, estradiol 45 pg/mL, progesterone 0.66 ng/mL, and total 
testosterone 1.09 ng/mL. Thyroid-stimulating hormone (TSH) 
and prolactin levels were normal. Transvaginal ultrasound showed 
that the right ovary measured 3.9 ×3.5 ×2.8 cm (19 cm
3) and the 
left ovary 3.0 ×2.8 ×2.5 (10 cm
3). The diagnosis was polycystic 
ovary syndrome (PCOS). We scheduled a GnRHa long protocol 
for controlled ovarian stimulation. On the 54th day of the cycle, 
a depot preparation of triptorelin (3.75 mg Decapeptyl CR; Fer-
ring, Malmo, Sweden) was administered subcutaneously. Seven 
days later, the patient complained of mild abdominal discom-
fort. An ultrasound revealed multiple follicles ranging from 15 
to 28 mm in diameter (Fig. 1). Her exam results were: estradiol 
2,560 pg/mL, LH 9.83 IU/L, FSH 2.24 IU/L, and progesterone 
4.18 ng/mL. Since serum estradiol concentrations were consid-
ered appropriate for the number of follicles present, a decision 
was made to continue the oocyte donation cycle. The patient 
received 10,000 IU of hCG. Thirty-five hours later oocyte retriev-
al was performed and 5 oocytes were aspirated. Three oocytes 
fertilized and underwent subsequent cleavage. Three embryos Park HT, et al.  •  GnRH-Agonist and Ovarian Hyper-Response
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were transferred to the recipient, none of which resulted in preg-
nancy.
  Afterwards, the patient underwent another cycle. On the 42nd 
day of her cycle (FSH 5.96 IU/L, LH 10.78 IU/L, estradiol 41 pg/
mL, progesterone 0.54 ng/mL), a short-acting preparation of trip-
torelin (Decapeptyl; Ferring) was administered s.c. at a dose of 
0.05 mg per day, which is half of the conventional dosage. Three 
days later, her ovaries were quiescent on ultrasound. Seven and 
ten days after the initiation of GnRHa, an ultrasound revealed no 
evidence of functional ovarian cyst. Administration of 150 IU re-
combinant FSH (gonal-F; Serono Inc., Rockland, MA, USA) was 
started, which she received daily for 7 days. The dosage was later 
increased to 225 IU for an additional 5 days. On day 13, her estra-
diol concentration reached 1,756 pg/mL. She received 10,000 
IU hCG and underwent oocyte retrieval 35 hr later. A total of 11 
oocytes were retrieved, and three embryos were transferred to 
the recipient. A single gestational sac and fetal pulse was detect-
ed upon ultrasound at 7 weeks.
DISCUSSION
It is unclear what led to the exaggerated response to GnRHa in 
this case. One possible explanation is the initial flare-up caused 
by GnRHa, which induced the release of gonadotropins from 
the pituitary thereby stimulating the growth of ovarian follicles. 
These follicles acquired FSH-independent growth dynamics, 
which finally led to mature follicles by relatively abundant LH. 
The high serum concentrations of LH (9.83 IU/L) may support 
this scenario. It is accepted that in the late stages of follicle devel-
opment, granulosa cells become receptive to LH stimulation and 
LH becomes active (7). Our patient was lean-PCOS. In PCOS, 
LH secretion is characterized by greater sensitivity to GnRH, as 
compared to women without PCOS. These responses to GnRH 
are more prominent in lean-PCOS (8); for this reason, we spec-
ulate that the serum LH concentration remained high for ten 
days following the initiation of GnRHa due to an extremely high 
initial flare-up.
  Alternatively, previous researchers have suggested a direct ef-
fect of GnRHa at the ovarian level (3, 5, 9). The concentration of 
native GnRH in the systemic circulation is relatively low. Howev-
er, during treatment with GnRHa, high concentration of GnRHa 
circulate in the central and peripheral tissue. Many studies have 
investigated the effects of GnRHa on ovarian cell proliferation 
and steroidogenesis. In Bussenot et al. (10), 5 different GnRH 
agonists were compared based on their effect on estradiol secre-
tion in human granulosa lutein cell cultures. The results showed 
that buserelin and leuprolein significantly enhanced estradiol 
secretion. However, triptorelin, which was used in our case, had 
no effect on estradiol secretion in their study. 
  Recently, Azem et al. (11) reported a live birth following the 
administration of GnRHa without gonadotropins. They sched-
uled a conventional flare-up regimen on day 1 of the cycle (trip-
torelin 0.1 mg) and daily injections of gonadotropins from day 3 
and on. Contrary to their expectation, they observed that con-
tinued GnRHa injection without gonadotropins induced follic-
ular development with high estradiol levels until oocyte retriev-
al. However, it is unclear what course to follow in subsequent 
cycles, after ovarian hyperstimulation using only GnRHa in the 
first cycle, as very few case reports have been published on this 
topic. Weissman et al. (3) reported two cases of ovarian hyper-
stimulation following the administration of GnRHa without go-
nadotropins. They also reported that recurrent ovarian hyper-
stimulation occurred in subsequent cycles of the same patients. 
In the present report, the second cycle did not lead to ovarian 
hyperstimulation. The main difference between their cases and 
ours is the dose of GnRHa. While Weissman et al. (3) used a de-
pot preparation of triptorelin (first cycle) and short acting prep-
aration 0.1 mg/day in (subsequent cycle), we used triptorelin at 
0.05 mg/day. 
  However, we cannot say that the dose of GnRHa is only respon-
Fig. 1. Ultrasonographic finding of both ovaries. (A) Left ovary, (B) Right ovary.
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sible for different results. Some differences regarding patient’s 
characteristics and the timing of initiation of GnRHa should be 
considered.
  In summary, a small subgroup of patients may develop ovar-
ian hyperstimulation following the administration of GnRHa 
without gonadotropins. More attention should be paid to pa-
tient’s complaints during the use of GnRHa.
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